M
Modus Therapeutics
Swedish drug development company in clinical phase focused on normalizing the lives for patients with Sickle Cell Disease
About Modus Therapeutics
Modus Therapeutics is a Swedish biotechnology company focused on developing sevuparin, a novel therapeutic for treating diseases with high unmet medical needs. The company primarily targets conditions such as sepsis and septic shock, which are severe and often fatal. Modus Therapeutics operates in the healthcare and pharmaceutical market, collaborating with institutions like Imperial College London to advance clinical research. The business model revolves around the development and commercialization of sevuparin, aiming to bring this innovative treatment to market through clinical trials and regulatory approvals. Revenue is generated through partnerships, grants, and eventual sales of the approved drug. The company serves healthcare providers, hospitals, and patients suffering from critical conditions.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Founded
- 2011
- Headquarters
- Stockholm, Sweden
- Listing
- IPO 2021
- Sector
- Biotech & Life Sciences
Knowledge graph
More headlines
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A5 investors entered at this stage
Rosetta Capital
Praktikerinvest
Karolinska Development
Östersjöstiftelsen
HealthCap
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Modus Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Modus Therapeutics on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.